Cholangiocarcinoma

Malignancy of the bile ducts, often diagnosed late.

Key features

Painless jaundice, pruritus, weight loss; FGFR2/IDH1 actionable subsets.

Inheritance: Sporadic (FGFR2,IDH1)

Prevalence: ~1–2/100,000/yr

Submit Your Paper

Approved therapies

pemigatinib, futibatinib, ivosidenib

Patient organisation: Cholangiocarcinoma Foundation

Licensed under CC BY 4.0. Free to share with attribution to GMJ News.

Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, EULAR/ACR guidelines. Schema.org MedicalCondition structured data included.